scholarly journals Complete Response to Trastuzumab and Pertuzumab in Combination with Chemotherapy in HER2-positive Metastatic Breast Cancer—Case Series—

2019 ◽  
Vol 80 (3) ◽  
pp. 480-485
Author(s):  
Yasue TSUCHIDA ◽  
Naoki HAYASHI ◽  
Chie TOSHIKAWA ◽  
Yuji YAMASHITA ◽  
Koyu SUZUKI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Series ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Complete Response ◽  
Cancer Case ◽  
Her2 Positive

Experience with eribulin in triple-negative metastatic breast cancer: case studies

2018 ◽  
Vol 14 (7s) ◽  
pp. 13-20 ◽  
Author(s):  
Maria Isabel Gallegos Sancho ◽  
Raúl Márquez-Vázquez ◽  
Alfonso Sánchez-Muñoz
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Studies ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case

Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and Literature Review

2019 ◽  
Vol 130 ◽  
pp. 267-270
Author(s):  
Yoshifumi Tao ◽  
Kenji Yagi ◽  
Hirotake Nishimura ◽  
Keijirou Hara ◽  
Shunji Matsubara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Literature Review ◽  
Bone Cyst ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case

Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature

2013 ◽  
Vol 141 (2) ◽  
pp. 167-172 ◽  
Author(s):  
Eleonora Teplinsky ◽  
Derrick Cheung ◽  
Ilan Weisberg ◽  
Ramon E. A. Jacobs ◽  
Martin Wolff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Hepatitis B ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Review Of Literature ◽  
Hepatitis B Reactivation

Lapatinib efficacy according to metastatic sites in trastuzumab pretreated patients with HER2-positive metastatic breast cancer: An analysis form IntERB registry in the Czech Republic.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11072-e11072 ◽  
Author(s):  
Peter Grell ◽  
Vit Kandrnal ◽  
Bortlicek Zbynek ◽  
Rostislav Vyzula
Keyword(s):  
Breast Cancer ◽  
Czech Republic ◽  
Metastatic Breast Cancer ◽  
Kinase Inhibitor ◽  
Metastatic Breast ◽  
Skin Toxicity ◽  
Skeletal Metastasis ◽  
Complete Response ◽  
Her2 Positive ◽  
Metastatic Sites

e11072 Background: Lapatinib is an oral dual tyrosin kinase inhibitor of EGFR and HER2 and compared to trastuzumab penetrates to CNS. We evaluated efficacy and safety of lapatinib treatment according to different metastatic sites involvement using data from IntERB registry that has been initiated and run by Czech Society for Oncology and Institute of Biostatistics and Analyses at Masaryk University, Brno, Czech Republic. Methods: An analysis included 213 patients with HER2 positive metastatic breast cancer treated from January 2007 to September 2011. Lapatinib was mostly administered orally 1250mg/day with capecitabine (2000mg/m2 D1-14), 16 patients received lapatinib in monotherapy. All patients had experienced progression during prior trastuzumab based therapy. Results: Median age was 56 years (range 23 – 78). Median duration of lapatinib therapy was 20.6 weeks (range 1–146). Complete response was achieved in 13 patients (6.1%), partial response in 31 (14.6%), stable disease in 118 (55.4%). In 26 disease have progressed (12.2%); response could not be assessed in 25 patients (11.7%). PFS for whole group was 7.1 months (95% CI 5.9-8.5). Overall survival was 17.2m (95% CI 15.8-18.6), probability of 6m OS was 80.3% and 1-year OS was 64%. Metastatic sites specific survival was evaluated in 103 patients. CNS dissemination was initially diagnosed in 31 patients (30.1%), PFS in this group was 6.2m (95% CI 3.3-9.1), OS was not reached, 6-m OS was 67.3%. In non-CNS group (skeletal metastasis in 49.5%, lung 38.8%, hepatic 36.9%, lymphatic 17.5%, other 15.5%) was PFS 6.3m (95% CI 1.6-11.1), OS 22.0m (95% CI 15.3-28.8) and 6-m OS was 88.2%. Most common toxicities were diarrhea in 11.7% patients, rash/skin toxicity in 10.8%, nausea/vomitus in 5.2% and hepatotoxicity in 2.3%. No cardiac toxicity was reported. Therapy was discontinued due toxicity in 9.0%. Conclusions: Lapatinib in combination with capecitabine proved its efficacy in trastuzumab pretreated HER2 positive metastatic breast cancer. Even in patients with CNS involvement was achieved a notable PFS and OS, comparable to non-CNS group of patients. Therapy was well tolerated.

scholarly journals Subtrochanteric Fracture as First Sign of Metastatic Breast Cancer: Case Presentation

2015 ◽  
Vol 6 (8) ◽  
pp. 367-372
Author(s):  
Bogdan Deleanu ◽  
Radu Prejbeanu ◽  
Dan Crisan ◽  
Dinu Vermesan ◽  
Vlad Predescu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Subtrochanteric Fracture ◽  
Cancer Case ◽  
Case Presentation

scholarly journals The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature

2021 ◽  
Vol 11 ◽  
Author(s):  
Giovanna Garufi ◽  
Luisa Carbognin ◽  
Armando Orlandi ◽  
Antonella Palazzo ◽  
Giampaolo Tortora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Clinical Trials ◽  
Scientific Evidence ◽  
Case Series ◽  
Metastatic Breast ◽  
Signs And Symptoms ◽  
Breast Cancer Case ◽  
Clinical History ◽  
Cancer Case

The efficacy and safety of the combination of endocrine therapy (ET) and CDK4/6 inhibitors for patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer (BC) presenting with visceral crisis or life-threatening conditions represent a challenge for daily clinical practice. Indeed, the peculiarity of this clinical presentation (signs and symptoms of rapidly progressive disease) does not allow to include such patients in a trial aiming for drug approval. On the basis of the scientific evidence available so far, chemotherapy represents the standard of care according to guidelines, on the basis of the more rapid activity in comparison with ET alone. Besides, the combination of ET and CDK4/6 inhibitors have demonstrated in clinical trials to have clinically impactful activity in a short time, thus suggesting a potential role in advanced tumors that require rapid response. Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment. Considering that these peculiar cases are excluded from clinical trials, the estimation of the magnitude of the benefit of the newer ET combination may potentially represent a practical question for large case series and real-world studies.

Horner's syndrome as an initial sign of metastatic breast cancer: Case report

2007 ◽  
Vol 31 (6) ◽  
pp. 450-452 ◽  
Author(s):  
Sanja Kovacic ◽  
Arijana Lovrencic-Huzjan ◽  
Gordana Drpa ◽  
Josip Hat ◽  
Stanko Belina
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Horner’S Syndrome ◽  
Cancer Case ◽  
Horner's Syndrome ◽  
Initial Sign

scholarly journals The Oncological Emergency Case: Paraneoplastic Hypoglycemia in Metastatic Breast Cancer - Case Report and Brief Review of the Literature

Breast Care ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. 368-370 ◽  
Author(s):  
Lisa Richters ◽  
Monika Ortmann ◽  
Michael Faust ◽  
Stefan Krämer ◽  
Peter Mallmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Review Of The Literature ◽  
Emergency Case ◽  
Oncological Emergency
Sign in / Sign up

Export Citation Format

Share Document